Brian Lu with beaker and petri dishes

The UAB Comprehensive Diabetes Center is comprised of faculty members conducting basic, translational, and clinical research related to diabetes and its complications.

 Current areas of research include autoimmune type 1 diabetes, type 2 diabetes, diabetes complications, beta cell biology, oxidative stress, signaling and metabolism as well as diabetes risk factors, epidemiology, intervention studies, outcomes research, and drug discovery.

 With funding from national institutes, foundations, and donors, we perform cutting-edge diabetes research, provide comprehensive education and training, and uncover breakthroughs in treatment for those affected by diabetes in our community and beyond. Below is a list of examples of recent key peer-reviewed publications from the UCDC Young Diabetes Principle Investigator group and UCDC director and associate directors.

  1. LDB1-mediated transcriptional complexes are sensitive to islet stress.
    Liu Y, Kepple JD, Shalev A, S Hunter C.Islets. 2022 Dec 31;14(1):58-68. doi: 10.1080/19382014.2021.2016028.PMID: 34968409
  1. Heterogeneity of Diabetes: β-Cells, Phenotypes, and Precision Medicine: Proceedings of an International Symposium of the Canadian Institutes of Health Research's Institute of Nutrition, Metabolism and Diabetes and the U.S. National Institutes of Health's National Institute of Diabetes and Digestive and Kidney Diseases.
    Cefalu WT, Andersen DK, Arreaza-Rubín G, Pin CL, Sato S, Verchere CB, Woo M, Rosenblum ND; Symposium planning committee, moderators, and speakers:, Rosenblum N, Cefalu W, Andersen DK, Arreaza-Rubín G, Dhara C, James SP, Makarchuk MJ, Pin CL, Sato S, Verchere B, Woo M, Powers A, Estall J, Hoesli C, Millman J, Linnemann A, Johnson J, Pin CL, Hawkins M, Woo M, Gloyn A, Cefalu W, Rosenblum N, Huising MO, Benninger RKP, Almaça J, Hull-Meichle RL, MacDonald P, Lynn F, Melero-Martin J, Yoshihara E, Stabler C, Sander M, Evans-Molina C, Engin F, Thompson P, Shalev A, Redondo MJ, Nadeau K, Bellin M, Udler MS, Dennis J, Dash S, Zhou W, Snyder M, Booth G, Butte A, Florez J.Diabetes Care. 2022 Jan 1;45(1):3-22. doi: 10.2337/dci21-0051.
  1. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
    Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, Sørrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators.JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001/jama.2021.23619.PMID: 35015037 
  1. Mother-child cardiometabolic health 4-10 years after pregnancy complicated by obesity with and without gestational diabetes.
    Martin SL, Zhang L, Callahan ML, Bahorski J, Lewis CE, Hidalgo BA, Durant N, Harper LM, Battarbee AN, Habegger K, Moore BA, Everett A, Aslibekyan S, Sertie R, Yi N, Garvey WT, Chandler-Laney P.Obes Sci Pract. 2022 Feb 16;8(5):627-640. doi: 10.1002/osp4.599. eCollection 2022 Oct.PMID: 36238222 
  1. Islet transplantation into brown adipose tissue can delay immune rejection.
    Kepple JD, Barra JM, Young ME, Hunter CS, Tse HM.JCI Insight. 2022 Feb 22;7(4):e152800. doi: 10.1172/jci.insight.152800.PMID: 35015736
  1. Is Obesity or Adiposity-Based Chronic Disease Curable: The Set Point Theory, the Environment, and Second-Generation Medications.
    Garvey WT.Endocr Pract. 2022 Feb;28(2):214-222. doi: 10.1016/j.eprac.2021.11.082. Epub 2021 Nov 22.PMID: 34823000
  1. Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes.
    Xu G, Grimes TD, Grayson TB, Chen J, Thielen LA, Tse HM, Li P, Kanke M, Lin TT, Schepmoes AA, Swensen AC, Petyuk VA, Ovalle F, Sethupathy P, Qian WJ, Shalev A.Nat Commun. 2022 Mar 3;13(1):1159. doi: 10.1038/s41467-022-28826-3.PMID: 35241690
  1. New Horizons. A New Paradigm for Treating to Target with Second-Generation Obesity Medications.
    Garvey WT.J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1339-e1347. doi: 10.1210/clinem/dgab848.PMID: 34865050 
  1. Subcutaneous Administration of a Nitric Oxide-Releasing Nanomatrix Gel Ameliorates Obesity and Insulin Resistance in High-Fat Diet-Induced Obese Mice.
    Ren G, Hwang PTJ, Millican R, Shin J, Brott BC, van Groen T, Powell CM, Bhatnagar S, Young ME, Jun HW, Kim JA.ACS Appl Mater Interfaces. 2022 May 4;14(17):19104-19115. doi: 10.1021/acsami.1c24113. Epub 2022 Apr 25.PMID: 35467831 
  1. Deletion of Gdf15 Reduces ER Stress-induced Beta-cell Apoptosis and Diabetes.
    Xu G, Chen J, Jo S, Grayson TB, Ramanadham S, Koizumi A, Germain-Lee EL, Lee SJ, Shalev A. 2022 May 1;163(5):bqac030. doi: 10.1210/endocr/bqac030.PMID: 35290443
  1. FGF21-FGFR4 signaling in cardiac myocytes promotes concentric cardiac hypertrophy in mouse models of diabetes.
    Yanucil C, Kentrup D, Li X, Grabner A, Schramm K, Martinez EC, Li J, Campos I, Czaya B, Heitman K, Westbrook D, Wende AR, Sloan A, Roche JM, Fornoni A, Kapiloff MS, Faul C.Sci Rep. 2022 May 5;12(1):7326. doi: 10.1038/s41598-022-11033-x.PMID: 35513431
  1. Associations between cardiometabolic disease severity, social determinants of health (SDoH), and poor COVID-19 outcomes.
    Howell CR, Zhang L, Yi N, Mehta T, Cherrington AL, Garvey WT.Obesity (Silver Spring). 2022 Jul;30(7):1483-1494. doi: 10.1002/oby.23440. Epub 2022 May 25.PMID: 35352489
  1. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
    Cusi K, Isaacs S, Barb D, Basu R, Caprio S, Garvey WT, Kashyap S, Mechanick JI, Mouzaki M, Nadolsky K, Rinella ME, Vos MB, Younossi Z.Endocr Pract. 2022 May;28(5):528-562. doi: 10.1016/j.eprac.2022.03.010.PMID: 35569886 
  1. Changes in Type 2 Diabetes Trends in Children and Adolescents During the COVID-19 Pandemic.
    Schmitt JA, Ashraf AP, Becker DJ, Sen B.J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2777-e2782. doi: 10.1210/clinem/dgac209.PMID: 35377436 
  1. Diagnostic Test Accuracy of Urine C-peptide Creatinine Ratio for the Correct Identification of the Type of Diabetes: A Systematic Review.
    Pappachan JM, Sunil B, Fernandez CJ, Lahart IM, Ashraf AP.touchREV Endocrinol. 2022 Jun;18(1):2-9. doi: 10.17925/EE.2022.18.1.2. Epub 2022 May 23.PMID: 35949364 
  1. Guidelines on models of diabetic heart disease.
    Heather LC, Hafstad AD, Halade GV, Harmancey R, Mellor KM, Mishra PK, Mulvihill EE, Nabben M, Nakamura M, Rider OJ, Ruiz M, Wende AR, Ussher JR.Am J Physiol Heart Circ Physiol. 2022 Jul 1;323(1):H176-H200. doi: 10.1152/ajpheart.00058.2022. Epub 2022 Jun 3.PMID: 35657616 
  1. The Ldb1 transcriptional co-regulator is required for establishment and maintenance of the pancreatic endocrine lineage.
    Toren E, Liu Y, Bethea M, Wade A, Hunter CS.FASEB J. 2022 Aug;36(8):e22460. doi: 10.1096/fj.202200410R.PMID: 35881062
  1. Examining the evidence for weight management in individuals with type 2 diabetes.
    Garvey WT, Umpierrez GE, Dunn JP, Kwan AYM, Varnado OJ, Konig M, Levine JA.Diabetes Obes Metab. 2022 Aug;24(8):1411-1422. doi: 10.1111/dom.14764. PMID: 35545861 
  1. Cathepsin D Drives the Formation of Hybrid Insulin Peptides Relevant to the Pathogenesis of Type 1 Diabetes.
    Crawford SA, Wiles TA, Wenzlau JM, Powell RL, Barbour G, Dang M, Groegler J, Barra JM, Burnette KS, Hohenstein AC, Baker RL, Tse HM, Haskins K, Delong T.Diabetes. 2022 Aug 30:db220303. doi: 10.2337/db22-0303.PMID: 36041196
  1. Extracellular vesicles in β cell biology: Role of lipids in vesicle biogenesis, cargo, and intercellular signaling.
    Aguirre RS, Kulkarni A, Becker MW, Lei X, Sarkar S, Ramanadham S, Phelps EA, Nakayasu ES, Sims EK, Mirmira RG.Mol Metab. 2022 Sep;63:101545. doi: 10.1016/j.molmet.2022.101545. Epub 2022 Jul 8.PMID: 35817393
  1. Carbonyl Posttranslational Modification Associated With Early-Onset Type 1 Diabetes Autoimmunity.
    Yang ML, Connolly SE, Gee RJ, Lam TT, Kanyo J, Peng J, Guyer P, Syed F, Tse HM, Clarke SG, Clarke CF, James EA, Speake C, Evans-Molina C, Arvan P, Herold KC, Wen L, Mamula MJ.Diabetes. 2022 Sep 1;71(9):1979-1993. doi: 10.2337/db21-0989.PMID: 35730902
  1. Cross Talk Between Insulin and Glucagon Receptor Signaling in the Hepatocyte.
    Habegger KM.Diabetes. 2022 Sep 1;71(9):1842-1851. doi: 10.2337/dbi22-0002.PMID: 35657690
  1. Pharmacologic Weight Management in the Era of Adolescent Obesity.
    Raman V, Gupta A, Ashraf AP, Breidbart E, Gourgari E, Kamboj M, Kohn B, Krishnan S, Lahoti A, Matlock K, Mehta S, Mistry S, Miller R, Page L, Reynolds D, Han JC.J Clin Endocrinol Metab. 2022 Sep 28;107(10):2716-2728. doi: 10.1210/clinem/dgac418.PMID: 35932277 
  1. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses.
    Kosiborod MN, Bhatta M, Davies M, Deanfield JE, Garvey WT, Khalid U, Kushner R, Rubino DM, Zeuthen N, Verma S.Diabetes Obes Metab. 2022 Oct 6. doi: 10.1111/dom.14890. Online ahead of print.PMID: 36200477
  1. Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice.
    Kim T, Nason S, Antipenko J, Finan B, Shalev A, DiMarchi R, Habegger KM.Diabetes. 2022 Oct 1;71(10):2123-2135. doi: 10.2337/db21-1018.PMID: 35877180
  1. Alpha Cell Thioredoxin-interacting Protein Deletion Improves Diabetes-associated Hyperglycemia and Hyperglucagonemia.
    Lu B, Chen J, Xu G, Grayson TB, Jing G, Jo S, Shalev A.Endocrinology. 2022 Oct 11;163(11):bqac133. doi: 10.1210/endocr/bqac133.PMID: 35957590
  1. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.
    Blonde L, Umpierrez GE, Reddy SS, McGill JB, Berga SL, Bush M, Chandrasekaran S, DeFronzo RA, Einhorn D, Galindo RJ, Gardner TW, Garg R, Garvey WT, Hirsch IB, Hurley DL, Izuora K, Kosiborod M, Olson D, Patel SB, Pop-Busui R, Sadhu AR, Samson SL, Stec C, Tamborlane WV Jr, Tuttle KR, Twining C, Vella A, Vellanki P, Weber SL.Endocr Pract. 2022 Oct;28(10):923-1049. doi: 10.1016/j.eprac.2022.08.002. Epub 2022 Aug 11.PMID: 35963508
  1. Economic outcomes of antiobesity medication use among adults in the United States: A retrospective cohort study.
    Watkins S, Toliver JC, Kim N, Whitmire S, Garvey WT.J Manag Care Spec Pharm. 2022 Oct;28(10):1066-1079. doi: 10.18553/jmcp.2022.22116. Epub 2022 Jul 20.PMID: 35856489
  1. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
    Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, Jódar E, Kandler K, Rigas G, Wadden TA, isletWharton S; STEP 5 Study Group.Nat Med. 2022 Oct;28(10):2083-2091. doi: 10.1038/s41591-022-02026-4. Epub 2022 Oct 10.PMID: 36216945 
  1. Extracellular vesicles in β cell biology: Role of lipids in vesicle biogenesis, cargo, and intercellular signaling.
    Aguirre RS, Kulkarni A, Becker MW, Lei X, Sarkar S, Ramanadham S, Phelps EA, Nakayasu ES, Sims EK, Mirmira RG.Mol Metab. 2022 Sep;63:101545. doi: 10.1016/j.molmet.2022.101545. Epub 2022 Jul 8.PMID: 35817393